-
Mashup Score: 0Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease - 2 day(s) ago
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Patient Case: Pathology of Graft Versus Host Disease - 3 day(s) ago
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Axatilimab Trial Results - 3 day(s) ago
Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Monitoring and Mitigating Adverse Events - 9 day(s) ago
Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Safety Concerns with Ruxolitinib - 11 day(s) ago
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 33
Treatments that aid inflammation resolution, immune tolerance, and epithelial repair may improve outcomes beyond high-dose corticosteroids and other b…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Clinical Evolution of Treatment in Chronic Graft vs. Host Disease - 2 month(s) ago
Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Yi-Bin Chen, MD, outlines the goals and challenges of communicating with his patient and explores the roles of first-line and second-line therapies in the management of chronic #GVHD. @MGHCancerCenter https://t.co/kw23vijNkb